Merck said the FDA wants trial data that include U.S. patients, after the Harmony CRL. Executives said the maturity of U.S. data matters more than the percentage of U.S. patients. They also described MK1084 as well tolerated.
MRK · Merck & Co., Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Thomas H. Glocer notified the Board he intends to retire at the 2027 Annual Meeting of Shareholders, with no disagreement with the Company. Douglas M. Baker, Jr. will become independent lead director effective Jan. 1, 2027, succeeding Mr. Glocer.
Merck recorded a $9.0 billion R&D charge after acquiring Cidara Therapeutics, Inc. for $9.2 billion in May 2026. Worldwide sales increased 5% to $18.1 billion in the third quarter of 2026 amid pricing pressure.
Merck reported third-quarter 2026 sales of $18,085 million, up 5%, with GAAP EPS of $2.04 and non-GAAP EPS of $2.49, both including a one-time $0.12 per share charge tied to a SciBrunch license agreement. Full-year 2026 sales are now expected between $66.8 billion and $67.3 billion. Non-GAAP EPS guidance was narrowed and raised to between $2.77 and $2.82.
Merck & Co., Inc. elected Paul J. Diaz to its Board of Directors effective November 1, 2026, appointed him to the Audit Committee and Research Committee, and expanded the Board to 14 members. Diaz will stand for shareholder election in May 2027.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 4, 2026TL;DR. Second-quarter sales rose 5% to $16.6 billion and full-year revenue guidance was raised to $66.3 to $67.3 billion, with FDA approval of Lipfendra. Non-GAAP results were a $0.13 per share loss on the $2.31 per share Terns charge, and Keytruda growth is expected to moderate.
- + Total worldwide sales rose 5% to $16.6 billion, or 4% excluding foreign exchange.
- + Full-year 2026 revenue guidance was raised and narrowed to $66.3 to $67.3 billion.
- + WINREVAIR sales rose 75% to $588 million on continued demand in pulmonary arterial hypertension.
- + Keytruda family sales rose 4% to $8.4 billion, driven by earlier-stage cancer uptake.
- + Positive TroFuse-005 results showed sac-TMT improved overall survival and progression-free survival versus chemotherapy in certain endometrial cancer patients.
- + FDA approved Lipfendra, the first and only once-daily oral PCSK9 inhibitor to reduce LDL-C in adults with hypercholesterolemia.
- − Non-GAAP loss per share was $0.13, driven by a $2.31 per share charge for the Terns acquisition.
- − Full-year non-GAAP EPS guidance includes one-time charges of $3.62 per share for Cidara and $2.31 per share for Terns.
- − Non-GAAP gross margin fell 1.1 percentage points to 81.1%, mainly on higher inventory reserves.
- − JANUVIA/JANUMET sales fell 31% to $429 million on competition and lower demand.
- − Total U.S. Keytruda growth is expected to moderate, and about $250 million of Q3 2025 wholesaler timing will not repeat.
- − Third-quarter sales will be affected by the unwind of second-quarter specialty pharmacy purchases.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Research
our published analysis of this companyEquibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Alliance Revenue - Lynparza | $352M | FY2026 Q3 | -7.1% |
|
|
|||
| Alliance Revenue - Reblozyl | $177M | FY2026 Q3 | +30.1% |
|
|
|||
| ANIMAL HEALTH | $1.68B | FY2026 Q3 | +3.8% |
|
|
|||
| Capvaxive sales | $263M | FY2026 Q3 | +7.8% |
|
|
|||
| Gardasil/Gardasil 9 sales | $2B | FY2026 Q3 | +14.1% |
|
|
|||
| Januvia | $186M | FY2026 Q3 | -51.3% |
|
|
|||
| Keytruda | $7.77B | FY2026 Q3 | -4.6% |
|
|
|||
| Keytruda Qlex | $830M | FY2026 Q3 | +16500.0% |
|
|
|||
| Ohtuvayre sales | $184M | FY2026 Q3 | — |
|
|
|||
| Vaxneuvance sales | $195M | FY2026 Q3 | -13.7% |
|
|
|||
| Welireg sales | $307M | FY2026 Q3 | +56.6% |
|
|
|||
| Winrevair | $694M | FY2026 Q3 | +92.8% |
|
|
|||
| Alliance Revenue - Koselugo | $10M | the three months ended June 30, 2026 filing | — |
| International sales | $7.24B | the three months ended June 30, 2026 filing | — |
| M-M-R II sales | $96M | the three months ended June 30, 2026 filing | — |
| Non-GAAP EPS assuming dilution non-GAAP | -$0.13 | the three months ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP EPS assuming dilution as reported under GAAP -$0.54
+$0.41 EPS difference
= Non-GAAP EPS assuming dilution -$0.13
|
|||
| Non-GAAP income (loss) before taxes non-GAAP | $550M | the three months ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP (Loss) income before taxes as reported under GAAP -$683M
+$1.09B Acquisition- and divestiture-related costs
+$334M Restructuring costs
-$191M Income from investments in equity securities, net
= Non-GAAP income (loss) before taxes $550M
|
|||
| Non-GAAP net (loss) income attributable to Merck & Co., Inc. non-GAAP | -$330M | the three months ended June 30, 2026 filing | — |
| ProQuad sales | $235M | the three months ended June 30, 2026 filing | — |
| U.S. sales | $9.37B | the three months ended June 30, 2026 filing | — |
| Varivax sales | $260M | the three months ended June 30, 2026 filing | — |
| Animal Health Sales | 1.8B | the second quarter of 2026 | — |
| BRAVECTO line of products sales | 359M | the second quarter of 2026 | — |
| BRIDION | 497M | the second quarter of 2026 | — |
| Gross margin | 73.5% | the second quarter of 2026 | — |
| JANUVIA/JANUMET | 429M | the second quarter of 2026 | — |
| KEYTRUDA/KEYTRUDA QLEX Sales | 8.4B | the second quarter of 2026 | — |
| LAGEVRIO | 5M | the second quarter of 2026 | — |
| Non-GAAP effective income tax rate non-GAAP | 160.3% | the second quarter of 2026 | — |
| Non-GAAP gross margin non-GAAP | 81.1% | the second quarter of 2026 | — |
| Non-GAAP net (loss) income non-GAAP | -$330M | Second Quarter 2026 | — |
| Other Revenues related to the receipt of milestone payments for out-licensed products | $132M | June YTD 2026 | — |
| PREVYMIS | 295M | the second quarter of 2026 | — |
| PROQUAD, M-M-R II and VARIVAX | 592M | the second quarter of 2026 | — |
| total alliance revenue for Koselugo | $171M | June YTD 2026 | — |
| Total Vaccines sales | $4.68B | June YTD 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MRK
this stock
Merck & Co., Inc.
|
$327.41B | +26.2% | +1.3% | 136.9 | 1.1% |
|
LLY
ELI LILLY & Co
|
$1.27T | +25.7% | +44.7% | 43.9 | 0.8% |
|
JNJ
Johnson & Johnson
|
$643.09B | +29.1% | +6.0% | 40.6 | 0.7% |
|
ABBV
AbbVie Inc.
|
$501.19B | +24.1% | +8.6% | 48.8 | 0.9% |
|
NVS
Novartis AG
|
$285.60B | +9.7% | — | — | 0.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 19, 2026
- This year
- 27
Merck said the FDA wants trial data that include U.S. patients, after the Harmony CRL. Executives said the maturity of U.S. data matters more than the percentage of U.S. patients. They also described MK1084 as well tolerated.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MRK | -9.6% | -9.8% | +15.3% | -11.2% | +26.2% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -4.2% | -3.5% | +21.0% | -5.9% | +21.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.